In an article published online in Nature Communications, scientists from SomaLogic and Yale University report that they have successfully generated a novel Slow Off-rate Modified Aptamer (SOMAmer) molecule that binds tightly to interleukin 1 alpha (IL-1α), an essential inflammatory protein implicated in cancer and other diseases.
read moreNews Press Release Archive
News Archive
Protein changes may signal side effects in drug trials
In an article published “early online” in the American Heart Association journal Circulation, researchers at Pfizer, the Karolinska Institute, the University of California, San Francisco and SomaLogic describe how the measurement of blood-based protein changes in response to treatment with an experimental drug candidate may improve the efficiency and safety of clinical drug development.
read moreReynolds appointed CEO of SomaLogic
SomaLogic announced today that Board of Directors member Alister W. (Al) Reynolds has agreed to become the next company Chief Executive Officer. He is replacing Byron Hewett, who elected to step down from the role following several years of successfully leading the company through its initial growth into a successful commercial entity.
read moreModified DNA aptamers: Two is better than one
In a study published online in the Proceedings of the National Academy of Sciences (PNAS), SomaLogic scientists report on the generation and characterization of a new class of SOMAmer that contains two different types of modified nucleotides.
read moreSomaLogic announces that it has joined the iCarbonX Digital Life Alliance
SomaLogic announced today that it has agreed to join the “Digital Life Alliance” established by iCarbonX, the China-based company founded in 2015 to build a “Global Digital Health Ecosystem that can define each person’s ‘digital life’ based on a combination of individual’s biological, behavioral and psychological data, the Internet and artificial intelligence.”
read moreLevels of nine blood proteins can accurately predict high or low risk of serious cardiovascular events
A study published online today in the Journal of the American Medical Association (JAMA) details the first successful effort to measure at scale the levels of more than a thousand proteins in blood in patients with coronary heart disease, and describes the identification of a combination of nine specific proteins whose levels taken together can accurately predict the risk of future heart attacks, strokes, heart failure or death.
read moreSomaLogic raises up to $60.5 million from Visium Healthcare Partners to support strategic growth initiatives
SomaLogic, Inc. and Visium Healthcare Partners, LP today announced that SomaLogic will receive up to $60.5 million through a combination of debt and equity financing from Visium. The proceeds will be used to support SomaLogic’s continued growth.
read moreThe University of Oxford and SomaLogic Announce wide-ranging agreement to use SOMAscan in translational research
The University of Oxford and SomaLogic announced today that they have agreed to undertake a number of collaborative projects that will employ SomaLogic’s proprietary SOMAmer reagents and SOMAscan assay technologies to discover and characterize protein biomarkers for a range of clinical diseases and conditions.
read moreMatthew (“Matt”) Norkunas, M.D., announced as new SomaLogic CFO
SomaLogic, Inc. announced today that Matthew Norkunas, M.D. has joined the company as Chief Financial Officer (CFO). Prior to SomaLogic, Dr. Norkunas was a Senior Research Analyst at Marsico Capital Management in Denver focused on biotech, pharma, life sciences, and diagnostics companies.
read moreSomaLogic completes agreement with Bristol-Myers Squibb for expanded access to SOMAmer reagents
SomaLogic, Inc. announced today that it signed an agreement with the Bristol-Myers Squibb Company (NYSE-BMY) to provide expanded access to its proprietary SOMAmer reagents. The agreement covers both the 1,310 reagents available in the current public version of the SOMAscan assay, as well as custom SOMAmer reagents developed through SomaLogic’s SOMAmer Discovery Service specifically for Bristol-Myers Squibb.
read more